Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report

• Main Authors: Yadong Wang (Author), Tiange Wang (Author), Jianchao Xue (Author), Ziqi Jia (Author), Xinyu Liu (Author), Bowen Li (Author), Ji Li (Author), Xiaoguang Li (Author), Weiwei Wang (Author), Zhongxing Bing (Author), Lei Cao (Author), Zhili Cao (Author), Naixin Liang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Tumour lysis syndrome (TLS) represents a group of fatal metabolic derangements resulting from the rapid breakdown of tumour cells. TLS typically occurs soon after the administration of chemotherapy in haematologic malignancies but is rarely observed in solid tumours. Here, we report a case of brigat...